← Leaderboards
William R Wilson
Stanford University
$1,031,456
Attributed
$1,031,456
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $297.3K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,031,456 · 1
By mechanism
P01$1,031,456 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- John Martin Brown$14,329,263
- Amato J. Giaccia$32,506,927
- William A Denny$1,029,490
- Quynh-Thu X Le$15,492,013
- Furqan Fazal$1,770,497
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogCytotoxicityHypoxiaTirapazamineAthymic MouseDrug Design /Synthesis /ProductionAntineoplasticsDrug MetabolismCisplatinClostridiumNeoplastic CellLaboratory MousePharmacokineticsLiquid Chromatography Mass SpectrometryDrug Screening /EvaluationDrug Adverse EffectHigh Throughput TechnologyRetina DisorderBiological Transport, ActiveBinding (Molecular Function)AttentionBeta-GlucuronidaseBeta GlucuronidaseAccounting
Grant awards (8)
Mechanism-based Optimization of Tirapazamine Analogs$297,336
P01 · FY2008 · CA · contact PI
Mechanism-based Optimization of Tirapazamine Analogs$295,203
P01 · FY2007 · CA · contact PI
Mechanism-based Optimization of Tirapazamine Analogs$150,651
P01 · FY2006 · CA · contact PI
Mechanism-based Optimization of Tirapazamine Analogs$146,262
P01 · FY2005 · CA
Mechanism-based Optimization of Tirapazamine Analogs$142,004
P01 · FY2004 · CA
EXTRAVASCULAR PENETRATION, HOST TOXICITY OF TIRAPAZAMINE$0
P01 · FY2002 · CA
EXTRAVASCULAR PENETRATION, HOST TOXICITY OF TIRAPAZAMINE$0
P01 · FY2001 · CA
EXTRAVASCULAR PENETRATION, HOST TOXICITY OF TIRAPAZAMINE$0
P01 · FY2000 · CA